On the basis of our findings that the interaction of PR-DPR and NOVA1 causes CE inclusion of UNC13A mRNA and decreased protein expression, we would like to establish a novel therapeutic strategy for C9-ALS targeting this abnormal interaction. Here, C9 is linked to amyotrophic lateral sclerosis.